Search | Clinical Trials Finder

Conditions: Insomnia
Interventions: Repeated Transcranial magnetic stimulation (rTMS); Other
Lead sponsor: Stanford University; Other
Eligibility: 25 Years to 45 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Pain, Postoperative, Total Knee Arthroplasty (TKA)
Interventions: Continuous Femoral Nerve Block, Nerve Block, Continuous Adductor Canal, Continuous Sciatic Nerve Block, Bupivacaine; Procedure · Drug
Lead sponsor: Kevin King, DO; Other
Eligibility: 18 Years to 75 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Dementia
Interventions: Namenda; Drug
Lead sponsor: Stanford University; Other
Eligibility: 50 Years to 65 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Stanford, California

Conditions: Healthy
Interventions: ACT-128800; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Nemiralisib, Itraconazole; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Oral Bacterial Infection, Mechanical Ventilation Complication
Interventions: SwishKit + Oral care treatment as usual, Oral care treatment as usual; Device · Procedure
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Prosthetic-joint Infection
Interventions: Benzoyl Peroxide Topical, Electrocautery surgical skin incision; Drug · Procedure
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, DEN 2.5 mg, DEN 7.5 mg, DEN 15 mg, DEN 30 mg, DEN 45 mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 36
States / cities: Long Beach, California • Pasadena, California • Denver, Colorado + 32 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Lixisenatide (AVE0010), Lixisenatide Placebo, Pen auto-injector, Sitagliptin, Sitagliptin Placebo, Metformin; Drug · Device
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 21
States / cities: Montgomery, Alabama • Muscle Shoals, Alabama • Mesa, Arizona + 17 more

Conditions: Phenylketonuria
Interventions: Kuvan, Diet; Drug · Other
Lead sponsor: University of Miami; Other
Eligibility: 4 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Diabetes type2
Interventions: Control: CHO Blend, Experimental: CHO Blend plus AN100; Other
Lead sponsor: Abbott Nutrition; Industry
Eligibility: 40 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Kent, Ohio

Conditions: Renal Transplant Infection
Interventions: Study Group, Control Group; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 99 Years
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Venous Thromboembolism, Metastatic Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma
Interventions: Kinisoquin™, Placebo; Drug
Lead sponsor: Quercis Pharma AG; Industry
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Ventura, California • Miami Lakes, Florida • Boston, Massachusetts

Conditions: Autism, Sleep Disturbances in Children, Sleep
Interventions: Power Down bedtime manipulation; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 6 Years to 10 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hepatic Impairment
Interventions: Omaveloxolone 50 mg capsules; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Tustin, California • Miami, Florida • Orlando, Florida

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: Xalacom, Xalatan, Timolol; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 528 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 64
States / cities: Birmingham, Alabama • Flagstaff, Arizona • Artesia, California + 52 more

Conditions: Dementia, Elderly, Sleep
Interventions: Control Condition, Individualized Social Activities (ISA), Physical Resistance Training and Walking (PRT/walking), Combined ISA/PRT/walking; Behavioral
Lead sponsor: National Institute of Nursing Research (NINR); NIH
Eligibility: 55 Years and older
Enrollment: 355 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Sjögren Syndrome
Interventions: Remibrutinib, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Duchenne Muscular Dystrophy (DMD)
Interventions: Prednisone, Placebo; Drug
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 3 Years to 6 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Opioid-Induced Constipation
Interventions: Linaclotide 145 micrograms, Linaclotide 290 micrograms, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 77
States / cities: Anniston, Alabama • Foley, Alabama • Phoenix, Arizona + 67 more

Conditions: Colorectal Cancer, Head and Neck Cancer
Interventions: Doxycycline, Hydrocortisone 1% cream, Sunscreen, Moisturizer, Clindamycin, Medrol-dose pack (Steroid); Drug · Other
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Non Alcoholic Steatohepatitis
Interventions: Saroglitazar Magnesium 2mg, Saroglitazar Magnesium 4mg, Placebos; Drug
Lead sponsor: Zydus Therapeutics Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 6
States / cities: Jackson, Mississippi • Germantown, Tennessee • Hermitage, Tennessee + 2 more

Conditions: Asthma
Interventions: FF/UMEC/VI (100/31.25/25) mcg, FF/UMEC/VI (100/62.5/25) mcg, FF/UMEC/VI (200/31.25/25) mcg, FF/UMEC/VI (200/62.5/25) mcg, FF/VI (100/25) mcg, FF/VI (200/25) mcg, Fluticasone/salmeterol (FSC), Albuterol/salbutamol, ELLIPTA DPI, DISKUS DPI, METERED-DOSE INHALER (MDI); Drug · Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 2,436 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 99
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 89 more

Conditions: Autism Spectrum Disorder
Interventions: MINDful TIME, Mindfulness Mobile App; Behavioral
Lead sponsor: Nicole Matthews, Ph.D.; Other
Eligibility: 13 Years to 18 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Phoenix, Arizona

Search by objective public record fields.

Optimizing the Timing of rTMS to Enhance the Administration of Insomnia Treatment

Continuous Adductor Canal Blocks Vs. Low Dose Femoral Nerve Blocks For Early Rehabilitation After Total Knee Arthroplasty

Treatment With Namenda in Women at Risk for Cognitive Decline

Study to Evaluate the Pharmacokinetics, Tolerability, and Safety of ACT-128800 in Japanese and Caucasian Healthy Male and Female Subjects

A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics (PK) of Nemiralisib

Efficacy of A Novel RinSe Device to Reduce Oral Bacteria in Intubated IntEnsive CaRe Patients: a Pilot Study

Benzoyl Peroxide and Electrocautery Skin Incision to Eradicate Cutibacterium Acnes

A New Oral Treatment For Type II Diabetes Mellitus

24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years

Kuvan Therapy in Phenylketonuria (PKU): The Effect of Blood Phenylalanine Concentration on Kuvan Response

Benefits of Nutritional Ingredients for Type 2 Diabetes

Conversion to Envarsus Post Kidney Transplant Protects Against BK Infection

The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer

Differences in Rest, Emotion, and Arousal Modulation in Youth

A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic Function

A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma

Effect of Activities and Exercise on Sleep in Elderly Persons With Dementia

A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome

A Trial of Chronotherapy of Corticosteroids in Duchenne Muscular Dystrophy

Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain

Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients

Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

Telehealth Mindfulness-based Intervention for Adolescents With Autism Spectrum Disorder and Their Caregivers